Yingying Miao1, Guifeng Liu2,3, Lin Liu4,5. 1. Department of Anesthesiology, Union Hospital of Jilin University, Changchun, 130033, People's Republic of China. 2. Department of Anesthesiology, Union Hospital of Jilin University, Changchun, 130033, People's Republic of China. liuguifenggf@126.com. 3. Department of Radiology, Union Hospital of Jilin University, No. 126, Xiantai Street, Changchun, 130033, Jilin, People's Republic of China. liuguifenggf@126.com. 4. Department of Anesthesiology, Union Hospital of Jilin University, Changchun, 130033, People's Republic of China. liu_linllllll@163.com. 5. Department of Radiology, Union Hospital of Jilin University, No. 126, Xiantai Street, Changchun, 130033, Jilin, People's Republic of China. liu_linllllll@163.com.
Abstract
OBJECTIVE: Osteosarcoma (OS) is a malignant tumor characterized by the direct production of bone or osteoid tissues by proliferating tumor cells. Suppressor of variegation 3-9 homolog 2 (SUV39H2) is implicated in the occurrence of OS. Therefore, we designed this study to investigate effects of SUV39H2 in OS meditated by the lysine specific demethylase-1/E-cadherin (LSD1/CDH1) axis. METHODS: Clinical OS tissues and paracancerous tissues were collected for analysis of SUV39H2, LSD1 and CDH1 expression, and Kaplan-Meier survival analysis was applied to test the relationship between SUV39H2 expression and overall survival. Loss- and gain-of-function assays were conducted to determine the roles of SUV39H2, LSD1 and CDH1 in OS epithelial mesenchymal transition (EMT) and migration in OS cells, with quantitation of relevant proteins by immunofluorescence. We confirmed the effects of modulating the SUV39H2/CDH1 axis in a mouse OS tumor model. RESULTS: SUV39H2 and LSD1 were highly expressed, while CDH1 was downregulated in OS tissues and cells. SUV39H2 expression correlated inversely with overall survival of patients with OS. SUV39H2 positively regulated LSD1 expression, while LSD1 negatively regulated CDH1 expression. SUV39H2 or LSD1 overexpression, or CDH1 silencing promoted migration and EMT, as indicated by reduced E-cadherin and dramatically upregulated Vimentin and N-cadherin of OS cells. SUV39H2 expedited the progression of OS, which was reversed by CDH1 repression in the setting of OS in vitro and in vivo. CONCLUSIONS: Collectively, our results demonstrate highly expressed SUV39H2 in OS elevates the expression of LSD1 to downregulate CDH1 expression, thereby aggravating OS, providing a potential therapeutic target for treatment of OS.
OBJECTIVE:Osteosarcoma (OS) is a malignant tumor characterized by the direct production of bone or osteoid tissues by proliferating tumor cells. Suppressor of variegation 3-9 homolog 2 (SUV39H2) is implicated in the occurrence of OS. Therefore, we designed this study to investigate effects of SUV39H2 in OS meditated by the lysine specific demethylase-1/E-cadherin (LSD1/CDH1) axis. METHODS: Clinical OS tissues and paracancerous tissues were collected for analysis of SUV39H2, LSD1 and CDH1 expression, and Kaplan-Meier survival analysis was applied to test the relationship between SUV39H2 expression and overall survival. Loss- and gain-of-function assays were conducted to determine the roles of SUV39H2, LSD1 and CDH1 in OS epithelial mesenchymal transition (EMT) and migration in OS cells, with quantitation of relevant proteins by immunofluorescence. We confirmed the effects of modulating the SUV39H2/CDH1 axis in a mouseOS tumor model. RESULTS:SUV39H2 and LSD1 were highly expressed, while CDH1 was downregulated in OS tissues and cells. SUV39H2 expression correlated inversely with overall survival of patients with OS. SUV39H2 positively regulated LSD1 expression, while LSD1 negatively regulated CDH1 expression. SUV39H2 or LSD1 overexpression, or CDH1 silencing promoted migration and EMT, as indicated by reduced E-cadherin and dramatically upregulated Vimentin and N-cadherin of OS cells. SUV39H2 expedited the progression of OS, which was reversed by CDH1 repression in the setting of OS in vitro and in vivo. CONCLUSIONS: Collectively, our results demonstrate highly expressed SUV39H2 in OS elevates the expression of LSD1 to downregulate CDH1 expression, thereby aggravating OS, providing a potential therapeutic target for treatment of OS.
Entities:
Keywords:
E-cadherin gene; Histone methyltransferases; Lysine specific demethylase-1; Osteosarcoma; Suppressor of variegation 3–9 homolog 2
Authors: Sharadha Sakthikumar; Ingegerd Elvers; Jaegil Kim; Maja L Arendt; Rachael Thomas; Jason Turner-Maier; Ross Swofford; Jeremy Johnson; Steven E Schumacher; Jessica Alföldi; Erik Axelsson; C Guillermo Couto; William C Kisseberth; Mats E Pettersson; Gad Getz; Jennifer R S Meadows; Jaime F Modiano; Matthew Breen; Marcin Kierczak; Karin Forsberg-Nilsson; Voichita D Marinescu; Kerstin Lindblad-Toh Journal: Cancer Res Date: 2018-05-03 Impact factor: 12.701
Authors: D Weekes; T G Kashima; C Zandueta; N Perurena; D P Thomas; A Sunters; C Vuillier; A Bozec; E El-Emir; I Miletich; A Patiño-Garcia; F Lecanda; A E Grigoriadis Journal: Oncogene Date: 2015-09-21 Impact factor: 9.867